Skin cancer

Skin cancer can involve melanocytes, leading to melanoma, but there are other non-melanoma skin cancers. These include basal cell carcinoma, squamous cell carcinoma and, less commonly, Merkel cell carcinoma, Kaposis sarcoma and T-cell lymphoma of the skin.

Featured

News & Views | 21 April 2022

Gut microbes as biomarkers of ICI response — sharpening the focus
- Neal Bhutiani
- & Jennifer A. Wargo
Nature Reviews Clinical Oncology, 1-2

Latest Research and Reviews

Research
13 May 2022 | Open Access

Melanopsin (Opn4) is an oncogene in cutaneous melanoma

Melanopsin (Opn4) is identified as an oncogene in cutaneous melanoma, with the loss of Opn4 found to be associated with reduced proliferation and tumor growth, due to changes in immune responses and Mitf signaling in vitro and in vivo.
- Leonardo Vinícius Monteiro de Assis
- , José Thalles Lacerda
- & Ana Maria de Lauro Castrucci
Communications Biology 5, 461
Research
11 May 2022 | Open Access

Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies

Rähni et al profile antibody response in patients with varied response to cancer immunotherapies. They identify antibody epitope responses that predict anti-cancer immunity elicited by immunotherapy.
- Annika Rähni
- , Mariliis Jaago
- & Kaia Palm
Communications Medicine 2, 48
Research | 10 May 2022

Association of HPV42 with digital papillary adenocarcinoma and the use of in situ hybridization for its distinction from acral hidradenoma and diagnosis at non-acral sites
- Chad Vanderbilt
- , Thomas Brenn
- & Klaus J. Busam
Modern Pathology, 1-6
Research
09 May 2022 | Open Access

The Rho guanosine nucleotide exchange factors Vav2 and Vav3 modulate epidermal stem cell function
- L. Francisco Lorenzo-Martín
- , Mauricio Menacho-Márquez
- & Xosé R. Bustelo
Oncogene, 1-14
Research | 04 May 2022

Landscape of helper and regulatory antitumour CD4⁺ T cells in melanoma

A survey of the CD4⁺ T cells in human melanomas indicates that immune evasion is mediated through direct stimulation of neoantigen-specific tumour-reactive regulatory T cells by HLA class II-positive melanoma cells.
- Giacomo Oliveira
- , Kari Stromhaug
- & Catherine J. Wu
Nature 605, 532-538
Research
04 May 2022 | Open Access

MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling
- Qiushuo Shen
- , Yanfei Han
- & Yongbin Chen
Signal Transduction and Targeted Therapy 7, 147

All Research & Reviews

News and Comment

News & Views | 21 April 2022

Gut microbes as biomarkers of ICI response — sharpening the focus

Two recent large-cohort studies reinforce the potential predictive capability of gut microbiota for immune-checkpoint inhibitor response and toxicities in patients with melanoma. However, additional investigations are required to understand the mechanistic underpinnings of this complex multifaceted relationship, and how it can be exploited for personalized cancer care.
- Neal Bhutiani
- & Jennifer A. Wargo
Nature Reviews Clinical Oncology, 1-2
Research Highlights | 19 April 2022

Pembrolizumab reduces recurrence risk in stage II melanoma
- David Killock
Nature Reviews Clinical Oncology 19, 359
Editorial | 23 March 2022

NCOA3, a new player in melanoma susceptibility and a therapeutic target
- Vladimir Bezrookove
- & Mohammed Kashani-Sabet
Cancer Gene Therapy 29, 399-401
Comments & Opinion | 24 January 2022

Un-Fair Skin: racial disparities in acral melanoma research

In this Comment article, Alicea and Rebecca advocate for increased basic research and translational studies of acral lentiginous melanoma using the patient communities that suffer the most in order to develop therapies that benefit patients across all ethnic and racial groups.
- Gretchen M. Alicea
- & Vito W. Rebecca
Nature Reviews Cancer 22, 127-128
Research Highlights | 14 January 2022

LAG3 inhibition improves outcomes
- Peter Sidaway
Nature Reviews Clinical Oncology 19, 149
Research Highlights | 06 January 2022

HIV and skin cancer risk

People with HIV who delay initiation of anti-retroviral therapy have permanent loss of memory T cells in the skin, which may explain their increased risk of skin cancer.
- Karen O’Leary
Nature Medicine

All News & Comment

Skin cancer

Featured

Gut microbes as biomarkers of ICI response — sharpening the focus

Latest Research and Reviews

Melanopsin (Opn4) is an oncogene in cutaneous melanoma

Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies

Association of HPV42 with digital papillary adenocarcinoma and the use of in situ hybridization for its distinction from acral hidradenoma and diagnosis at non-acral sites

The Rho guanosine nucleotide exchange factors Vav2 and Vav3 modulate epidermal stem cell function

Landscape of helper and regulatory antitumour CD4⁺ T cells in melanoma

MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling

News and Comment

Gut microbes as biomarkers of ICI response — sharpening the focus

Pembrolizumab reduces recurrence risk in stage II melanoma

NCOA3, a new player in melanoma susceptibility and a therapeutic target

Un-Fair Skin: racial disparities in acral melanoma research

LAG3 inhibition improves outcomes

HIV and skin cancer risk

Quick links

Discover content

Publishing policies

Author & Researcher services

Libraries & institutions

Advertising & partnerships

Career development

Regional websites

Legal & Privacy

Skin cancer

Featured

Related Subjects

Latest Research and Reviews

News and Comment

Search

Quick links